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Here, we describe a 79-year-old man, admitted to our unit for worsening diplopia
and fatigue, started a few weeks after an episode of bronchitis and flu vaccination.
Past medical history includes myasthenia gravis (MG), well-controlled by Pyridostigmine,
Azathioprine, and Prednisone. During the first days, the patient developed progressive
ocular movement abnormalities up to complete external ophthalmoplegia, severe limb
and gait ataxia, and mild dysarthria. Deep tendon reflexes were absent in lower limbs.
Since not all the symptoms were explainable with the previous diagnosis of myasthenia
gravis, other etiologies were investigated. Brain MRI and cerebrospinal fluid analysis
were normal. Electromyography showed a pattern of predominantly sensory multiple
radiculoneuritis. Suspecting Miller Fisher syndrome (MFS), the patient was treated
with plasmapheresis with subsequent clinical improvement. Antibodies against GQ1b
turned out to be positive. MFS is an immune-mediated neuropathy presenting with
ophthalmoplegia, ataxia, and areflexia. Even if only a few cases of MFS overlapping with
MG have been described so far, the coexistence of two different autoimmune disorders
can occur. It is always important to evaluate possible differential diagnosis even in case
of known compatible diseases, especially when some clinical features seem atypical.
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BACKGROUND
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction characterized
by fatigability and fluctuating weakness of voluntary muscles, leading to symptoms such as
diplopia, palpebral ptosis, dysphagia, dyspnea, or limb weakness. Disease exacerbations can
be triggered by concomitant infections, vaccination, or administration of certain antibiotics.
Antibodies against acetylcholine receptor (AchR), muscle-specific kinase (MuSK), and low-density
lipoprotein receptor-related protein 4 (LRP4) may be found on serum. Treatment generally
involves symptomatic therapy with acetylcholinesterase inhibitors and immunosuppression,
despite initiation of high doses of steroids can precipitate symptoms.
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CASE PRESENTATION
A 79-year-old man was admitted to our emergency room
complaining fatigue, generalized weakness, nausea, and
worsening of usual diplopia, following an episode of bronchitis
treated with cephalosporins. Moreover, he received flu
vaccination a few weeks before the onset.
MG was diagnosed 8 years earlier after the onset of lid ptosis
and head drop (class IIA according to the MGFA classification).
Antibodies against acetylcholine receptor (AChR) and ryanodine
receptor (RyR) were detected, but chest CT scan was negative
for thymoma. So far, clinical symptoms had always been well-
controlled by pyridostigmine, azathioprine, and low doses of
steroids. Last neurological examination, performed 2 months
earlier, revealed only mild diplopia on left lateral gaze after
prolonged fixation.
The patient also suffered from a mild iatrogenic chronic
sensorimotor axonal polyneuropathy due to chemotherapy
administered after surgical resection of colon cancer;
he also underwent ablation of two metastatic lesions in
the liver, but the subsequent oncological follow-up was
reported negative.
On admission, neurological examination revealed diplopia on
lateral gaze, limitation in upward gaze, mild ptosis of the left
eye after prolonged fixation, uncertainties at finger-to-nose test,
mild proximal limb muscles fatigability, and absence of knee and
Achilles reflexes. Brain CT scan and chest X-rays were negative.
A putative diagnosis of worsening of myasthenia gravis was
made and the patient was hospitalized due to concerns of
respiratory failure, considering the age and the recent infection.
Absence of lower limbs deep tendon reflexes was initially
ascribed to the polyneuropathy. On admission, taking into
account the mild presenting symptoms and the absence of
respiratory involvement, Prednisone and Azathioprine dosages
were increased (respectively from 7.5 to 12.5 and from 50 to
75mg), withholding standard treatments for MG exacerbation,
such as intravenous immunoglobulin or plasmapheresis.
In the first days of hospitalization, the patient developed
progressive worsening of ocular movement abnormalities with
horizontal and vertical gaze limitation, mild fluctuating diplopia
in primary and lateral gaze, nystagmus on left lateral gaze, limb
ataxia, and wide-based gait with multi-directional sways during
Romberg maneuver. Additional findings included partial ptosis
of the left eye, hands tingling, mild proximal weakness in lower
limb, dysarthria, and facial asymmetry; nausea and episodes of
vomiting persisted.While ophthalmoparesis could be compatible
with MG, other clinical features suggested a different etiology.
Despite the fact that one of the most common presentations
of MG is represented by ocular symptoms, acute bilateral
ophthalmoparesis can be also attributed to various
etiologies (Table 1).
Blood tests were unremarkable, except for mild
hypercholesterolemia and increase of inflammatory indexes
(C-reactive protein 0.71 mg/dl—normal value < 0.5 mg/dl;
erythrocyte sedimentation rate 35—normal value < 20). Thyroid
function, serum folic acid, and vitamin B12 dosages were normal.
Antibodies against AChR and GQ1b were dosed.
TABLE 1 | Causes of acute bilateral ophthalmoparesis.
Brainstem
Stroke
Hemorrhage
Tumor
Multiple sclerosis
Wernicke encephalopathy
Cranial nerves
Diabetic or vascular complications
Tuberculous meningitis and other infections
Guillain-Barrè or Miller-Fisher syndrome
Cavernous sinus
Neuromuscular junction
Botulism
Myasthenia gravis
Muscles
Myositis
Mitochondriopathies
Orbit
Cellulitis
Graves disease
Electromyography, performed after 5 days from the symptom
onset, revealed mildly increased latency of the compound muscle
action potential (CMAP) of the right facial nerve and moderate
chronic neurogenic abnormalities in the muscles innervated by
the right L5 and the right C5–C6 nerve roots; right tibial and
right ulnar nerve F-wave latency was normal. Repetitive nerve
stimulation did not show a decremental response.
Brain MRI revealed only mild chronic cerebrovascular disease
and mild cortical and subcortical atrophy, without signs of acute
cerebral lesions or Wernicke’s encephalopathy (Figures 1A,B).
Clinical symptoms worsened up to complete external
ophthalmoplegia and inability to walk unsupported with
almost complete disappearance of upper limb reflexes. Another
electromyography was repeated 3 days later, displaying a
predominantly sensory polyradiculoneuropathy, characterized
by increased facial nerve latency and absence of sural, ulnar, and
radial sensory nerve action potentials (SNAP) (Figure 1C); ulnar
nerve F-wave seemed not clearly detectable.
Cerebrospinal fluid (CSF) analysis, including virological
investigations, was performed 6 days after symptom onset and
resulted unremarkable, without albuminocytological dissociation
(cells < 1/mmc, proteins 24 mg/dl). Serum and CSF oligoclonal
banding were absent.
Oncological screening, including neoplastic markers and full-
body CT scanwith contrast, performed due to themedical history
of the subject, was negative for malignancies.
The workup suggested a diagnosis of acute
polyradiculoneuropathy; thus, the patient was treated with
five sessions of plasmapheresis, leading to stabilization of the
clinical features and subsequent slow mild clinical improvement,
especially of limb ataxia and, at a lesser extent, of gait ataxia and
diplopia. Nausea and episodes of vomiting decreased too.
Antibodies against ganglioside GQ1b turned out to be positive
at high titer on serum (IgM 1/2560 and IgG 1/5120; cut-off
< 1/640), confirming the diagnosis of Miller-Fisher syndrome
(MFS). Antibodies against AChR were positive but lower
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FIGURE 1 | (A) Axial fluid attenuated inversion recovery (FLAIR) image demonstrated cortico-subcortical atrophy and chronic cerebrovasculopathy. (B) Diffusion
weighted imaging (DWI) did not show acute lesions. (C) Neurophysiological studies showed absence of the left sural and the right ulnar sensory nerve action
potentials, mildly increased latency of the facial nerve CMAP, and normal repetitive facial nerve stimulation.
compared to the last known titer (36.3 pmol/ml→ 7.2 pmol/ml;
normal values < 0.5 pmol/ml).
At discharge, the patient still presented severe
ophthalmoparesis (only minimal ocular movements were
possible), exhaustible left palpebral ptosis, facial asymmetry,
gait ataxia (need for external support, maintenance of Romberg
with multi-directional swinging with closed eyes), and slight
weakness in proximal lower limb muscles, and brachioradialis
reflex reappeared, though greatly reduced.
The patient underwent a cycle of physiotherapy and
rehabilitation. After 2 months, without further therapy
modifications, he was able to walk independently and the
ophthalmoparesis markedly improved. Clinical evaluation
showed mild convergence strabismus in primary position, mild
limitation in horizontal and upward gaze, diplopia after 15 s on
left lateral gaze, mild ptosis in the left eye after exercise, presence
of the biceps and patellar reflexes, absence of limb or gait ataxia.
Last electromyography showed a slightly prolonged ulnar F wave
and persistence of the axonal sensory polyneuropathy.
DISCUSSION
Miller Fisher syndrome (MFS), a rare variant of Guillain-
Barrè syndrome (GBS), is an immune-mediated neuropathy
presenting with (1) ophthalmoparesis, (2) ataxia, and (3)
areflexia. Disease onset usually follows an upper respiratory
tract or a gastrointestinal infection. The most common
presenting symptom of MFS is diplopia due to bilateral external
ophthalmoplegia; ataxia is often severe but areflexia is not
always present; patients may also exhibit ptosis, pupillary
abnormalities (anisocoria, sluggish direct response to light,
light-near dissociation), mild limb weakness, facial nerve
involvement (∼30%), and autonomic dysfunction (∼10%).
Antibodies anti GQ1b (IgG) can be detected in the majority
of the patients (around 90%), but they might also be found in
patients with GBS with ophthalmoplegia, Bickerstaff ’s brainstem
encephalitis, acute ophthalmoparesis without ataxia, or ataxia
without ophthalmoparesis. Cytoalbuminologic dissociation is
present only in half of the patients. The clinical course
of MFS is generally self-limiting and resolves in weeks to
months with an excellent outcome; treatment with intravenous
immunoglobulin and plasmapheresis has been proposed, but
their usefulness in improving the clinical outcome is still not
well-established, except in cases of overlap with other subtypes
of GBS (1, 2).
Neurophysiological studies may be normal: sensory nerve
conduction studies may present abnormalities (reduced SAP
amplitude) in some patients (∼30%) and ∼15% of subjects
have an overlap of axonal GBS. Motor nerve conduction studies
and F-wave latencies are generally normal. In our patient, the
history of polyneuropathy and possibly overlap with GBS may
explain the neurophysiological findings, even if MFS cases with
prolonged F-wave latencies and reduced CMAP amplitudes have
been described in the literature (3).
While at first the patient’s symptoms could mimic an
exacerbation of myasthenia gravis, he later developed the
classical symptomatic triad of MFS and antibodies anti GQ1b
Frontiers in Neurology | www.frontiersin.org 3 August 2019 | Volume 10 | Article 823
Brusa et al. MFS/MG Overlap
confirmed the diagnosis. Despite several autoimmune diseases
can sometimes overlap between each other, only four cases of
MFS associated with MG have been described so far and have
been treated with IVIG or plasmapheresis (4–7). Even in our
subject, plasmapheresis was effective in limiting the progression
of symptoms.
It could be speculated that the underlying dysregulation of
the immune system leads to a predisposition to autoimmune
disorders targeting the motor unit. A possible trigger could
have been the upper respiratory tract infection, more typically
described in MFS/GBS, but also a role of the vaccination cannot
be ruled out since very rare cases of post-vaccinal MFS have been
described (8).
Considering that MG and MFS are both infrequent immune-
mediated disorders, the coexistence of these two diseases in the
same patient represents a very peculiar finding. At first, this
patient represented an even more difficult clinical challenge since
both disorders might present with ophthalmoplegia. Alongside
the description of a very rare co-occurrence of MG and
MFS, this case provides useful considerations for everyday
clinical practice. Indeed, a correct differential diagnosis is
fundamental for appropriate medical management, given the
different prognosis and evolution of distinct disorders. Therefore,
distinguishing the proper etiology of symptoms must always
remain a priority, especially in case of atypical or incomplete
presentations, confounding factors and partially compatible pre-
existing disorders.
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